RT Journal Article
T1 Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients
A1 Mondelo Macía, Patricia
A1 Rodríguez López, Carmela
A1 Valiña, Laura
A1 Aguín, Santiago
A1 León Mateos, Luis
A1 García González, Jorge
A1 Abalo, Alicia
A1 Rapado González, Óscar
A1 Suárez Cunqueiro, María Mercedes
A1 Díaz Lagares, Ángel
A1 Curiel, Teresa
A1 Calabuig Fariñas, Silvia
A1 Azkárate, Aitor
A1 Obrador Hevia, Antònia
A1 Abdulkader Nallib, Ihab
A1 Muinelo Romay, Laura
A1 Díaz Peña, Roberto
A1 López López, Rafael
K1 MET protein expression
K1 MET amplification
K1 Circulating free DNA (cfDNA)
K1 Circulating tumor cells (CTCs)
K1 Targeted therapy
K1 MET copy number
AB MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p <10−10) was determined. Furthermore, we evaluated two approaches to detect the presence of MET on circulating tumor cells (CTCs), using the CellSearch® and Parsortix systems and monitored patients under anti-EGFR treatment (n = 30) combining both cfDNA and CTCs analyses. This follow-up provides evidence for the potential of MET CN assessment when patients develop resistance to anti-EGFR therapy and a significant association between the presence of CTCs MET+ and the Overall Survival (OS) in head and neck cancer patients (P = 0.05; HR = 6.66). In conclusion, we develop specific and noninvasive assays to monitor MET status in cfDNA/CTCs and demonstrate the utility of plasma MET CN determination as a biomarker for monitoring the appearance of resistance to anti-EGFR therapy
PB MDPI
YR 2020
FD 2020
LK http://hdl.handle.net/10347/23879
UL http://hdl.handle.net/10347/23879
LA eng
NO Mondelo-Macía, P.; Rodríguez-López, C.; Valiña, L.; Aguín, S.; León-Mateos, L.; García-González, J.; Abalo, A.; Rapado-González, O.; Suárez-Cunqueiro, M.; Díaz-Lagares, A.; Curiel, T.; Calabuig-Fariñas, S.; Azkárate, A.; Obrador-Hevia, A.; Abdulkader, I.; Muinelo-Romay, L.; Diaz-Peña, R.; López-López, R. Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients. Cells 2020, 9, 522
NO This study was financed by all the donors who participated in the Liquid Biopsy Crowdfunding campaign in 2017. LMR is supported by Asociación Española Contra el Cancer (AECC). ADL is funded by a “Juan Rodés” contract (JR17/00016) from ISCIII
DS Minerva
RD 28 abr 2026